Osteoporosis is a skeletal disorder characterized by low bone density and microarchitectural deterioration of bony tissue. This results in an increase in fracture risk. The resulting fractures pose a major health problem. Hip, vertebral, and wrist fractures are most commonly associated with osteoporosis. The annual cost attributable to these fractures in England and Wales is £1.7 billion. Over 90% of the cost is due to hip fractures. The total cost of osteoporosis in the United States alone is estimated to be over $14 billion per year. These figures are expected to increase as the proportion of elderly people in society increases.

The age-specific risk of hip, vertebral, and wrist fracture among white people reveals that there is a steep increase in the incidence of fracture with age and there is a higher incidence in women than in men. By age 85, white women have about a 3% annual incidence of hip fracture (fig 1). The lifetime risk of osteoporotic fracture in 50 year old British white women has been estimated at 14% for the hip, 11% for the spine, and 13% for the radius. The corresponding figures in North American women are higher 17.5%, 15.6%, and 16% respectively. The remaining risk for any fragility fracture is about 40% in women and 13% in men. It is estimated that the annual incidence of hip fractures in the UK is around 60,000, that of radial fracture around 50,000, and that of clinically diagnosed vertebral fractures around 40,000. However, the true incidence of vertebral fractures is higher as many vertebral fractures, certainly more than two thirds and possibly as many as 85%, do not come to medical attention. The World Health Organisation has defined osteoporosis as a bone mineral density (BMD) more than 2.5 SDs below the young normal mean. Osteopenia is defined as BMD between 1 and 2.5 SDs below the young normal mean. According to these criteria, the frequency of osteoporosis among 50–59 year old whites is 4% taking into account BMD readings at the femoral neck. This figure rises to 52% in women aged 80 years or more.

**GEOGRAPHIC VARIATION**

There are significant differences in the incidence and impact of osteoporosis in different populations around the world. Hip fractures are much more common in whites than non-whites. Moreover, there is substantial variation within populations of a given race and gender. Age adjusted hip fracture rates are higher among residents of Scandinavia than among whites in North America or Oceania. Within European countries, hip fracture rates vary more than sevenfold from one country to another.

**SECULAR TRENDS**

It is estimated that the financial and health related costs of osteoporosis will rise in future generations. There are an estimated 323 million individuals aged 65 years or over at present; this number is expected to reach 1355 million by the year 2050. These demographic changes are expected to increase the number of hip fractures occurring among people 35 years and over throughout the world from 1.66 million in 1990 to 6.26 million in 2050. It is believed that currently around half of all hip fractures among elderly people in 1990 took place in Europe and North America. However, in view of the rapid ageing of the Asian population it is believed that by 2050 over half of all hip fractures will occur in Asia.

**MORTALITY AND MORBIDITY ASSOCIATED WITH FRACTURES**

The mortality rate in an elderly person with hip fracture approaches 20%. In those who survive this is a permanent decline in postural control and walking ability, and a further 15% die within a year of fracture. One third of elderly people who survive the initial hospital stay are permanently institutionalized. The morbidity is worse for vertebral fractures that occur secondary to mild to moderate trauma than for those associated with severe trauma. Survival at five years appears to be 72% in men and 84% in women. However, in patients suffering vertebral fractures secondary to mild to moderate trauma only 8% of...
the deaths were thought to be due to osteoporosis. It is thought that a significant proportion of the excess mortality in patients with vertebral fractures is due to the presence of comorbid conditions.

In a cohort of white women in the United States bone density per se was shown to be inversely related to mortality. It has been shown that there was a 20% increase in mortality for each standard deviation decrease in BMD.

In the United States about 7% of patients who survive all types of fragility fractures have some degree of permanent disability and 8% require long term nursing home care. Moreover, a 50 year old white woman in the United States has a 13% chance of experiencing fracture related functional decline after any fracture.

Multiple vertebral fractures may result in acute and chronic back pain, limitation of physical activity, and progressive kyphosis and height loss. The loss of functional capabilities might result in depression and low self esteem. Moreover pain and fear of additional fracture can cause decreased physical activity, which in turn worsens osteoporosis and therefore the risk of further fractures is increased.

Significant mortality and morbidity are associated with osteoporotic fractures.

### Box 1: Epidemiology

- Hip, vertebral, and wrist fractures are most commonly associated with osteoporosis.
- The annual cost attributable to these fractures in England and Wales is £1.7 billion.
- There is a steep increase in the incidence of fracture with age and there is a higher incidence in women than in men.
- The frequency of osteoporosis in 50–59 year old white women is 4% and 52% in women aged 80 years or more.

**Table 1** Risk factors

<table>
<thead>
<tr>
<th>Skeletal</th>
<th>Extraskeletal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced bone mineral density</td>
<td>Increasing age</td>
</tr>
<tr>
<td>Low body mass index</td>
<td>Previous falls</td>
</tr>
<tr>
<td>Bone architecture</td>
<td>Abnormal gait</td>
</tr>
<tr>
<td>Bone turnover</td>
<td>Poor coordination</td>
</tr>
<tr>
<td>Previous fractures</td>
<td>Dementia</td>
</tr>
</tbody>
</table>

**Bone mineral density**

It has been shown that the lower the BMD the higher the fracture risk. Bone mass can be assessed at a number of sites including the lumbar spine, the hip, the forearm, and other sites. The most commonly used technique is dual energy x-ray absorptiometry (DXA) at the hip and the spine.

**Body weight**

It has been shown in a number of studies that there is a negative correlation between low body mass index and peak bone mass. Moreover, low body mass index and weight loss are strongly associated with increased fracture risk.

**Cigarette smoking**

There is an inverse relationship between cigarette smoking and BMD. Many factors are believed to contribute to this including reduced body weight, an earlier menopause, and increased metabolic breakdown of exogenous oestrogen in women. In a meta-analysis, although there was no significant difference in bone density between smokers and non-smokers at age 50, bone density in women diminished by 2% more in smokers than in non-smokers for each 10 year increase in age, with a difference between the two of 6% at age 80 years.

Moreover, an independent effect of cigarette smoking on the risk of hip fracture has been suggested by epidemiological studies.

**Alcohol consumption**

Consumption of large quantities of alcohol may be detrimental to bone. This might be due to adverse effects on protein and calcium metabolism, mobility, gonadal function, and a toxic effect on osteoblasts. However, moderate quantities of alcohol appear to be protective against bone loss at the hip and against the risk of vertebral fracture.

**Nutrition**

In a meta-analysis of many studies an association between calcium intake and bone mass was shown in premenopausal women. On the other hand, the relationship between calcium intake and fracture rate is not certain. In middle aged and elderly women a positive association has been reported between 25-hydroxyvitamin D concentration and BMD. An inverse relationship has been observed...
between serum parathyroid hormone and BMD. In addition, adequate vitamin D levels in the elderly may also improve muscle strength and reduce both the risk and consequences of falling.

**Physical inactivity**

It has been shown that physical loading and mechanical stress increase BMD and that certain forms of exercise may retard bone loss. Moreover, epidemiological studies have shown that a relationship exists between physical inactivity in the elderly and the risk of hip and vertebral fracture. Some of this effect might be due to the increased risk of falling.

**Sex hormone deficiency**

Primary hypogonadism is associated with low bone density in both sexes. In women with secondary amenorrhea the peak bone mass is reduced and the risk of osteoporosis is increased. Peak bone mass is also reduced by late menarche. Premature menopause, especially before the age of 45, is a strong determinant of bone loss and increased risk of fracture among women.

**Other causes**

Other causes of osteoporosis are:

- Endocrine disorders—for example, hypogonadism, hyperparathyroidism, Cushing's syndrome.
- Malignant disease—for example, myeloma, lymphoma.
- Drugs—for example, corticosteroids, heparin.
- Miscellaneous disorders—for example, connective tissue diseases, chronic renal failure.

**Genetic factors**

Studies in twins reveal that around 50% of the variance in peak bone mass is genetically determined. The hereditability is believed to be polygenic. In addition, genetic effects appear to be stronger in the lumbar spine than in the femoral neck or distal forearm.

**INVESTIGATIONS FOR THE DIAGNOSIS OF OSTEOPOROSIS**

In women, bone loss begins at or shortly before the menopause in the spine and as early as the mid-30s in the femoral neck. Bone mass is a major determinant of bone strength. Moreover, prospective studies have shown an increasing gradient of risk of fracture with decreasing bone density. Several methods are available for the assessment of bone mass. The method that is most widely used is the DXA scan. It has the ability to assess bone mass at both axial and appendicular sites, has high reproducibility, and the doses of radiation used are very low. Quantitative computed tomography enables measurement of cortical and cancellous bone in the spine or the peripheral skeleton. The disadvantages are that the equipment is expensive and the radiation dose is relatively high. The other available method is broadband ultrasonic velocity and attenuation of the os calcis, tibia, or patella. It is radiation-free, portable, and relatively cheap. However, it is unable to diagnose osteoporosis as defined by the World Health Organisation and has poor reproducibility. It still remains a research tool.

The absolute BMD for a given bone mass varies with different systems. Moreover, there are differences in the reference data provided by the manufacturer so that the same measured value may lie within different parts of the reference range depending on the system used. The presence of extraskeletal calcification, osteophytes, scoliosis and vertebral deformity, especially in elderly patients may affect the measurement of BMD.

**Clinical indications for bone densitometry**

At present population based screening using DXA cannot be justified. Patients should be measured only if there are strong clinical risk factors and if the result will influence the management of the patient. Strong risk factors include premature menopause (<45 years), prolonged secondary amenorrhea, and prolonged treatment with corticosteroids (>7.5 mg/day for six months or more). Moreover, bone densitometry should be used in patients with radiological evidence of osteopenia or vertebral deformity and those with a history of fragility fracture at the wrist, hip, or spine. Finally, bone densitometry should be used in the monitoring of therapy of osteoporosis—for example, patients on bisphosphonates.

In the spine and forearm effects of treatment can usually be detected within two years but in the femur three or more years may be required.

**Implications for the NHS**

In the UK it is estimated that 902 DXA scans per 100 000 population would be required each year (based on the national survey of DXA scan provision and epidemiological needs assessment). One hundred and forty seven would be for men and women with previous low trauma fracture, 194 for patients with radiographic evidence of osteopenia, 215 for patients on long term corticosteroids (>7.5 mg prednisolone daily for six months or more), 107 for patients with family history of osteoporosis, 107 for patients with other clinical risk factors (such as height loss, kyphosis, low body mass index, that is <19 kg/m²), and 78 for women with oestrogen deficiency (menopause or hysterectomy <45 years, secondary amenorrhea greater than six months not due to pregnancy, primary hypogonadism). Therefore, in an average health district of 300 000 people with the age and sex structure of the population of the UK facilities would be required to scan 2 706 men and women. On average DXA scans cost £48 for the lumbar spine and femoral neck and provision of such a service for a population of 300 000 would require £129 888 per year.

**PREVENTION AND TREATMENT OF OSTEOPOROSIS**

The aim of prevention and treatment is to prevent the occurrence of future fractures. Lifestyle changes that might help to diminish the frequency of osteoporosis and fractures should be encouraged. These include improving nutrition (that is, adequate calcium and vitamin D intake), maximising physical activity, reducing smoking, and avoiding heavy alcohol consumption. Moreover, attempts should be made to reduce the risk of falling for elderly people. Measures such as avoidance of loose rugs, improvement in lighting, correction of deficits in vision and hearing, avoidance of sedative drugs, and hip protectors among compliant nursing home residents will all help.

Moreover, treatment of the patient with osteoporosis requires supportive therapy, including analgesia, physiotherapy, hydrotherapy, and appropriate orthopaedic management in those with fracture of the hip, the radius or other long bones.

In patients with risk factors for osteoporosis and in those with previous fragility fractures the BMD should be measured, ideally by DXA scan. If the T score is normal—that is, above...
Frail, increased fall risk +/- housebound

Risk factors
Calcium + vitamin D Falls risk; Assessment/ advice and consider hip protectors

Previous fragility fracture

Measure BMD (DXA, hip +/- spine)

Normal
T score above –1

Osteopenia
T score –1 to –2.5

Osteoporosis
T score below –2.5

Reassure Lifestyle advice
Lifestyle advice Treat if previous fracture
Lifestyle advice Offer treatment
Alendronate Calcitonin Calcitriol Cyclic etidronate HRT Raloxifene (women) Risedronate Vitamin D + calcium

Figure 2 Management algorithm for men and women aged over 45 years who have or are at risk of osteoporosis (BMD, bone mineral density; DXA, dual energy x-ray absorptiometry; HRT, hormone replacement therapy). Derived from the Royal College of Physicians’ Guidelines.

—1—then the patient should be reassured and lifestyle advice provided. If the T score is in the osteopenic range—that is, from –1 to –2.5—then treatment should be offered if there has been a previous fracture. Otherwise, lifestyle advice should be provided and the DXA scan should be repeated after 12–18 months. If the BMD is in the osteoporotic range—that is, the T score is below –2.5—then treatment should be started and lifestyle advice provided (fig 2).

Pharmacological treatments
Bisphosphonates are synthetic analogues of inorganic pyrophosphate that inhibit bone resorption. Regimens include cyclical etidronate/calcium, risedronate, and alendronate. Cyclical etidronate/calcium is given as 400 mg of etidronate daily for 14 days followed by a calcium supplement of 500 mg daily for 76 days. Alendronate is given as a daily dose of 10 mg or 70 mg once weekly and risedronate as a daily dose of 5 mg. Calcium supplements are not included in the formulation but are advised in women with a low dietary calcium intake. The evidence for the antifracture efficacy of alendronate and risedronate, and cyclical etidronate for spinal fractures is substantial.

Number-needed-to-treat calculations suggest that 40 or fewer women with prevalent vertebral fractures and osteoporosis need treatment with alendronate or risedronate to prevent either a vertebral or non-vertebral fracture. In women with a low BMD, but no prevalent fractures, more women require treatment to prevent a fracture because fracture rates are much lower in this group.

Oestrogens can prevent bone loss around the menopause. Epidemiological studies suggest that oestrogens can prevent fractures of the radius, hip, and vertebrae.

When oestrogens are combined with progestagens the risk for endometrial cancer is not increased. However, bone loss restarts when oestrogen therapy is discontinued and the positive effects of therapy disappear in the following years. Therefore, oestrogen therapy should be prescribed for at least eight or 10 years, but the longer the use the greater the risk of breast cancer. It has been shown that good compliance with hormone replacement therapy (HRT) long term is achievable. The bone sparing dose of oestradiol is 2 mg daily, while that of conjugated equine oestrogen is 0.625 mg daily. The risks and benefits of HRT should be discussed with each individual patient. Testosterone can be considered in hypogonadal men.

Raloxifene is a non-steroidal benzo thiophene. It has been classified as a selective oestrogen receptor modulator and it inhibits bone resorption. In a long term, placebo controlled, double blind study raloxifene at doses of 30, 60, and 150 mg per day was shown to significantly increase the BMD of the lumbar spine, hip and total body, whereas those receiving placebo had decreases in BMD. The MORE (Multiple Outcomes ofRaloxifene Evaluation) trial revealed that raloxifene at doses of 60 and 120 mg per day significantly reduced the risk of new vertebral fracture in women with and without previous history of fracture compared with placebo. Moreover, all treatment arms experienced a significant increase in BMD compared with placebo. In addition, unlike oestrogen raloxifene does not appear to stimulate endometrial hyperplasia or increase the risk of breast cancer in postmenopausal women.

Calcitonin is a naturally occurring hormone, which inhibits bone resorption, decreases osteoclast formation and osteoclast attachment. In a randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis, a dose of 200 IU daily significantly reduced the risk of new vertebral fractures and the lumbar spine BMD increased significantly. In some patients with vertebral fractures calcitonin provides effective pain relief.

Intermittent parathyroid hormone injection restores bone strength by stimulation of new bone formation, thickening the cortices and existing trabeculae of the skeleton, and perhaps increasing trabecular numbers and their connectivity. It has been shown in a double blind, placebo controlled prospective study involving 1637 postmenopausal women with previous vertebral fractures that daily treatment with subcutaneous 1–34 fragment recombinant human parathyroid hormone 20 µg greatly reduced the incidence of new vertebral fractures (relative risk 0.35 and 0.31 respectively). The median treatment period was 24 months. The incidence of non-vertebral fragility fractures was reduced by 53% for both doses. There were significant increases of the BMD at the spine and the femoral neck. High dose parathyroid hormone occasionally caused nausea and vomiting. There was a dose dependent rise in serum calcium within 4–6 hours after injection that was mild and transient, occurring in 11% of patients who received parathyroid hormone 20 µg. Parathyroid hormone 20 µg per day has been submitted for approval for treatment of osteoporosis in the USA and Europe.

Calcium supplements should be given as an adjunct to other treatments. Calcium supplementation has a positive effect on BMD before the menopause and several years after the menopause but not in the perimenopausal period. Moreover, there is some evidence that calcium may prevent vertebral fractures. Vitamin D supplementation corrects vitamin D deficiency, suppresses secondary hyperparathyroidism, and increases BMD in the femoral neck. In a study in France, supplementation with vitamin D3 800 IU/day and calcium 1200 mg/day decreased the incidence of hip fractures and other peripheral fractures in nursing home residents who were vitamin D deficient and had a low calcium intake.
Calcitriol is the active metabolite of vitamin D. A daily dose of 0.25 µg twice daily may reduce the rate of new vertebral fractures in women with postmenopausal osteoporosis. Potential adverse effects include hypercalcemia and hypercalciuria and therefore plasma calcium should be monitored regularly.

Management of glucocorticoid induced osteoporosis

In the UK, more than 250 000 patients take continuous oral glucocorticoids. However, no more than 14% receive treatment to prevent bone loss, which is a major complication. Bone loss is highest in the initial months of treatment and between 30% and 50% of patients taking long term corticosteroids will experience fractures. Corticosteroid induced bone loss appears to be due to a combination of increased bone resorption and decreased bone formation caused by several mechanisms. Corticosteroids decrease the level of sex steroids, reduce the number and activity of osteoblasts, decrease intestinal calcium absorption, increase the resorption activity of osteoclasts, increase urinary calcium excretion, and increase bone cellular responsiveness to parathyroid hormone. Treatment should be considered for adults who will receive glucocorticoids at doses of 7.5 mg/day or more for six months or more. In the UK the most commonly used therapies are the bisphosphonates and HRT.

Box 2: Treatment

- No more than 14% of patients taking continuous oral glucocorticoids receive treatment to prevent bone loss.
- Treatment should be considered for adults who will receive glucocorticoids at doses of 7.5 mg/day or more for six months or more.
- In the UK the most commonly used therapies are the bisphosphonates and HRT.

Box 3: Key references


REFERENCES

ECHO

Preventing cardiogenic shock protects patients with acute MI

More patients admitted with acute myocardial infarction (MI) could be saved if cardiogenic shock (CS) was prevented, concludes a review.

Early recognition of cardiogenic shock is crucial but tricky, the authors say. Decreased peripheral blood flow despite sufficient volume indicates Cs, and in the time around infarction sustained hypotension and decreased peripheral blood flow. However, signs can vary. In particular, patients with anterior MI and tissue hypoxia but normal blood pressure should be assumed to have Cs. This pre-shock state has a very poor prognosis; if unrecognised and treated with beta blockers it will precipitate overt Cs.

The causes of Cs are left ventricular fibrillation—the most common—right ventricular fibrillation, and mechanical failure. In trials early revascularisation significantly improves survival, but only in patients under 75, and this is the treatment strategy endorsed by the ACC/AHA. The immediate priorities are resuscitation and maintaining arterial pressure. Aspirin and full dose heparin should be given. IABP is indicated for patients with ST elevation MI needing angiography and glycoprotein IIb/IIIa inhibitor for non-ST elevated MI.

Then judging the state of the heart and cardiac vessels is the crux of treatment—a task for a tertiary referral centre—and patients should be supported with prophylactic IABP before and during transfer. The classic anatomical picture is of triple vessel disease, left main disease, and decreased left ventricular function.

Cs often goes unrecognised, and though it often occurs soon after MI, many patients with ST or non-ST elevation MI die as a result.

Heart 2002;88:531–537.

Please visit the Postgraduate Medical Journal website (www.postgradmedj.com) for link to this full article.